Home>>Signaling Pathways>> Proteases>> Mitochondrial Metabolism>>Oligomycin D

Oligomycin D (Synonyms: 26-Demethyloligomycin A)

Catalog No.GC44506

Oligomycin D is a macrolide antibiotic produced by several species of Streptomyces that inhibits the mitochondrial F1FO-ATPase and is used to uncouple oxidative phosphorylation from electron transport.

Products are for research use only. Not for human use. We do not sell to patients.

Oligomycin D Chemical Structure

Cas No.: 1404-59-7

Size Price Stock Qty
500μg
$472.00
In stock
2.5mg
$1,061.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Oligomycin D is a macrolide antibiotic produced by several species of Streptomyces that inhibits the mitochondrial F1FO-ATPase and is used to uncouple oxidative phosphorylation from electron transport. [1] Oligomycin D is reported to inhibit K-Ras plasma membrane localization in MDCK cells with an IC50 value of 3.49 nM and is cytotoxic to SW620 colon cancer cells with an IC50 value of 36 µM.[2]

Reference:
[1]. Inoue, S., Mizutani, A., Sugita, R., et al. Purification and characterization of a novel protein activator of Ca2+/calmodulin-dependent protein kinase I. Biochemical and Biophysical Research Communications 215(3), 861-867 (1995).
[2]. Salim, A.A., Tan, L., Huang, X.-C., et al. Oligomycins as inhibitors of K-Ras plasma membrane localisation. Organic & Biomolecular Chemistry 14(2), 711-715 (2016).

Reviews

Review for Oligomycin D

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Oligomycin D

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.